Valuation: Gilead Sciences, Inc.

Market Cap 186B 3,213B 162B 153B 139B 261B 17,860B 262B 1,836B 708B 9,080B 699B 684B 29,217B P/E 2026 *
-45.4x
P/E 2027 * 18.7x
Enterprise Value 203B 3,502B 177B 167B 152B 284B 19,467B 285B 2,001B 772B 9,897B 762B 745B 31,845B EV / Sales 2026 *
6.61x
EV / Sales 2027 * 5.97x
Free-Float
99.88%
Yield 2026 *
2.19%
Yield 2027 * 2.23%
09-18 Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% MT
09-16 Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing MT
09-16 Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited CI
09-16 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
09-15 Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean CI
09-15 Gilead Sciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:45 AM
09-15 Gilead Sciences Expands Lenacapavir Access to 14 Countries MT
09-15 Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean RE
09-10 Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-10 HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating MT
09-09 Gilead Sciences, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 11:00 AM
09-08 Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead MT
09-08 Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead DJ
1 day-1.08%
Current month-0.68%
1 month+2.72%
3 months+15.87%
6 months-1.83%
Current year+10.39%
1 month 2,453.18
Extreme 2453.18
2,553.46
Current year 2,116
Extreme 2116
2,618.71
1 year 2,025.32
Extreme 2025.32
2,618.71
3 years 1,046.71
Extreme 1046.71
2,618.71
5 years 1,046.71
Extreme 1046.71
2,618.71
10 years 1,046.71
Extreme 1046.71
2,618.71
Manager TitleAgeSince
Chief Executive Officer 61 28/02/2019
Director of Finance/CFO 56 31/10/2019
Compliance Officer - 17/12/2025
Director TitleAgeSince
Director/Board Member 58 18/08/2016
Director/Board Member 73 31/12/2017
Director/Board Member 72 08/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-1.08%0.00% - - 186B
+0.04%+3.34%+51.12%+101.82% 1,028B
-0.09%+1.66%+55.02%+66.18% 651B
-0.02%+2.66%+18.91%+71.47% 466B
-1.22%+3.66%+36.44%+38.32% 346B
-0.79%+2.73%+19.03%+25.08% 266B
+0.58%+6.76%+11.13%+16.52% 259B
+1.55%+2.20%+39.81%+46.55% 208B
+0.79%+1.84%-28.27%-56.71% 191B
-0.52%+4.45%+32.12%+98.51% 186B
Average +0.07%+3.26%+26.15%+45.30% 400.19B
Weighted average by Cap. +0.17%+3.09%+35.15%+61.76%

Financials

2026 *2027 *
Net sales 30.7B 530B 26.77B 25.28B 22.96B 43.01B 2,946B 43.19B 303B 117B 1,498B 115B 113B 4,819B 32.68B 564B 28.5B 26.91B 24.44B 45.78B 3,136B 45.97B 322B 124B 1,594B 123B 120B 5,130B
Net income -4.27B -73.8B -3.73B -3.52B -3.2B -5.99B -410B -6.01B -42.16B -16.27B -209B -16.06B -15.7B -671B 10.28B 177B 8.96B 8.46B 7.68B 14.39B 986B 14.45B 101B 39.11B 501B 38.6B 37.74B 1,613B
Net Debt 16.75B 289B 14.6B 13.79B 12.52B 23.46B 1,607B 23.56B 165B 63.73B 817B 62.9B 61.51B 2,629B 9.12B 158B 7.96B 7.51B 6.82B 12.78B 876B 12.84B 89.99B 34.73B 445B 34.28B 33.52B 1,432B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
150.11USD
Average target price
158.15USD
Spread / Average Target
+5.35%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!